SCHEMBL8515191

SCHEMBL8515191

CCCCCNCC1CCCCC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 2/20 0.62
GNAO1 P09471 2/20 0.62
GNAI1 P63096 2/20 0.62
SAT1 P21673 1/20 0.53
CYP1A2 P05177 1/20 0.50
NAAA Q02083 1/20 0.49
ALDH1A1 P00352 1/20 0.48
TSHR P16473 1/20 0.48
EPHX1 P07099 9/20 0.47
EPHX2 P34913 2/20 0.46
METAP2 P50579 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27382583 1.00 GNAI3 (0.62) GNAI3GNAO1GNAI1SAT1CYP1A2
SCHEMBL8603624 0.98 GNAI3 (0.66) GNAI3GNAO1GNAI1SAT1CYP1A2
SCHEMBL28709614 0.98 GNAI3 (0.66) GNAI3GNAO1GNAI1SAT1CYP1A2
SCHEMBL11576183 0.98 GNAI3 (0.66) GNAI3GNAO1GNAI1SAT1CYP1A2
SCHEMBL28997937 0.98 GNAI3 (0.66) GNAI3GNAO1GNAI1SAT1CYP1A2
SCHEMBL11922711 0.98 GNAI3 (0.65) GNAI3GNAO1GNAI1SAT1CYP1A2
Hydrochloric Acid SCHEMBL3966575 0.96 GNAI3 (0.69) GNAI3GNAO1GNAI1SAT1CYP1A2
SCHEMBL9876649 0.94 GNAI3 (0.65) GNAI3GNAO1GNAI1SAT1CYP1A2
SCHEMBL842526 0.94 SAT1 (0.55) GNAI3GNAO1GNAI1SAT1CYP1A2
SCHEMBL18780243 0.92 GNAI3 (0.68) GNAI3GNAO1GNAI1SAT1NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236965-B2 Benzimidazole derivatives and their use as a medicament IPSEN PHARMA S.A.S. (FR) 2012-08-07 US disclosed
US-20090170922-A1 Benzimidazole derivatives and their use as a medicament SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) 2009-07-02 US disclosed
US-7495110-B2 Benzimidazole derivatives and their use as GnRH antagonists SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-02-24 US disclosed
WO-1999029705-A9 SIALYL LEWIS X AND SIALYL LEWIS A GLYCOMIMETICS GLYCOMED INC (US) 1999-11-11 WO disclosed
WO-1999029705-A2 SIALYL LEWIS X AND SIALYL LEWIS A GLYCOMIMETICS GLYCOMED INCORPORATED (US) 1999-06-17 WO disclosed
US-5733931-A ANTICHOLESTEROL AGENTS NISSIN FOOD PRODUCTS CO., LTD. (JP) 1998-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170922-A1 Benzimidazole derivatives and their use as a medicament GNRHR, FSHR, KISS1R GNAI3 549/4885GNAO1 859/4885GNAI1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.